1. Introduction
===============

Parvovirus was first described as a clinical entity causing haemorrhagic gastroenteritis in dogs in 1977 ([@bib2]) and the aetiological agent was named *Canine parvovirus* type 2 (CPV-2) to distinguish it from the antigenically unrelated virus, the *Canine parvovirus* type 1 (CPV-1), also known as minute virus of canines. Virus infection spread rapidly worldwide causing high rate of mortality in pups ([@bib7]). The dogs are infected through the oronasal route and after 3--10 days they develop an acute gastroenteritis characterised by loss of appetite, vomiting, fever, diarrhoea (from mucoid to haemorrhagic) and leukopenia.

CPV-2 contains a single-stranded DNA genome of about 5200 nucleotides, enclosed in an icosahedral capsid made up of two proteins, VP1 and VP2. Amino acids substitutions in VP2 sequence are known to cause changes in genetic and antigenic properties ([@bib36], [@bib46], [@bib47]). CPV-2 belongs to the feline parvovirus (FPV) subgroup of the genus *Parvovirus*, together with feline panleukopenia virus (FPLV), mink enteritis virus (MEV), raccoon parvovirus (RPV), raccoon dog parvovirus (RDPV) and blue fox parvovirus (BFPV) ([@bib4]). Its origin is unknown, but it was suggested that it arose as a mutant from FPLV in dog or cat populations or from related viruses in wild carnivores ([@bib47], [@bib49], [@bib44], [@bib45]).

After the first outbreak of CPV-2 infection, there were consecutive emergences of new antigenic variants of this virus, designated type 2a and 2b ([@bib37], [@bib38]). Starting from 1979 and in a relatively short period, these variants replaced the original type 2 worldwide in dogs ([@bib34], [@bib9], [@bib26], [@bib48], [@bib50], [@bib40], [@bib43], [@bib6], [@bib39]). CPV-2a and CPV-2b differ from the original type CPV-2 by amino acid changes affecting the VP2 protein and by their extended host range which includes canine and feline cells in vitro and dogs and cats in vivo. Subsequently, further mutations in the CPV capsid protein have been described in several countries, but there is no evidence for a further spread of these mutants ([@bib28]). Analysis of Italian CPV isolates revealed the onset in 2000 of an unusual CPV-2 mutant with a change (Asp → Glu) occurring in the strategic residue 426 of the capsid ([@bib5]). The Glu-426 mutant, also detected in other countries ([@bib35], [@bib20]), is widely distributed in Italy and is currently replacing CPV-2b in the Italian dog population ([@bib32], [@bib21], [@bib15], [@bib16], [@bib18]). In contrast with other mutations previously reported, such as Asp-300 and Pro-265, the mutation at residue 426 has probably provided the mutant with an evolutionary benefit. We are currently investigating whether this change really represents an advantage for viral spread and whether it has biological consequence ([@bib14]). Since the mutation Asp426Glu affects the major antigenic region, that has been taken into account for classification of the variants 2a and 2b ([@bib37], [@bib38]), the Glu-426 mutant has been referred to as new antigenic variant 2c ([@bib14], [@bib18]).

Molecular methods have been developed to quantify the viral loads in the faeces of dogs infected with CPV-2 ([@bib16]), characterise the CPV variants ([@bib18]) and discriminate between vaccine and field strains ([@bib17], [@bib19]).

In this study, by using real-time PCR, we investigated the pattern of distribution of the CPV variants in different tissues of dogs infected naturally.

2. Materials and methods
========================

2.1. Dogs
---------

The carcasses of twelve 3--4-month-old dogs, that had died as a consequence of single CPV infection within 4--5 days after the onset of the clinical signs, were selected from a previous study ([@bib18]). All dogs were mixed-bred and had been housed in different animal shelters of Italy until the occurrence of disease or death. By using real-time PCR assays based on minor groove binder (MGB) probe technology ([@bib18]), the dogs were found to be infected by CPV-2a (*n*  = 4), CPV-2b (*n*  = 4) or CPV-2c (*n*  = 4). Traditional and molecular methods ruled out co-infections by other common pathogens of dogs, such as *Bordetella bronchiseptica*, *Pasteurella multocida*, *Leptospira interrogans* ([@bib25]), reoviruses ([@bib30], [@bib13]), rotaviruses ([@bib24]), caliciviruses ([@bib29], [@bib31]), canine adenoviruses ([@bib27]), canine distemper virus ([@bib23]), canid herpesvirus ([@bib41]), canine coronavirus (CCoV) ([@bib11]).

2.2. Sampling and sample preparation
------------------------------------

Faecal samples from the rectal ampulla and tissue samples were collected from the dead dogs, including brain, cerebellum, cerebral bulb, tonsils, retropharyngeal and mesenteric lymph nodes, thymus, myocardium, lungs, liver, spleen, kidneys, bladder, bone marrow, jejunum, colon, rectum. Each tissue sample was withdrawn using disposable sterile scalpels.

Faecal samples were homogenised (10%, w/v) in phosphate buffered saline (PBS, pH 7.2) and subsequently clarified by centrifuging at 1500 ×  *g* for 15 min. DNA was extracted from faecal homogenates by boiling for 10 min and chilling on ice ([@bib42], [@bib53]), whereas nucleic acid purification from tissue samples was achieved by using the DNeasy Tissue Kit (Qiagen S.p.A., Milan, Italy), followed by final elution of DNA with 200 μl of AE buffer and storage at −70 °C until use. To reduce residual inhibitors of DNA polymerase activity to ineffective concentrations, the DNA extracts from both faecal and tissue samples were diluted 1:10 in distilled water ([@bib16]).

2.3. Real-time PCR with TaqMan probe for quantitation of CPV-2 DNA
------------------------------------------------------------------

The DNA extracts were tested by a TaqMan assay able to recognise all the CPV-2 strains ([@bib16]). The assay is internally controlled by using as exogenous DNA the nucleic acid extracted from ovine herpesvirus type 2 ([@bib10]). The reaction of real-time PCR (25 μl) contained 12.5 μl of master mix (Bio-Rad Laboratories Srl, Milan, Italy), 600 nM of primers (5′-AAACAGGAATTAACTATACTAATATATTTA-3′) and CPV-Rev (5′-AAATTTGACCATTTGGATAAACT-3′), 200 nM of probe CPV-Pb (5′-TGGTCCTTTAACTGCATTAAATAATGTACC-3′) and 10 μl of standard or template DNA. All standard dilutions and unknown samples were tested in duplicate. The following thermal protocol was used: activation of iTaq DNA polymerase at 95 °C for 10 min and 40 cycles consisting of denaturation at 95 °C for 15 s, primer annealing at 52 °C for 30 s and extension at 60 °C for 1 min.

3. Results
==========

The viral DNA titres found in the different tissues of the dogs infected naturally by types 2a, 2b and 2c are reported in [Fig. 1](#fig1){ref-type="fig"} . CPV-2 DNA was demonstrated in all tissues analysed, showing a very wide distribution of the virus in the organism. The highest viral loads were detected in the lymphoid tissues, with maximal titres observed in the tonsils of dogs infected with CPV-2c (median titre = 8.98 × 10^8^ DNA copies/10 μl of template) and in the spleen of dogs infected with CPV-2b (median titre = 7.33 × 10^8^ DNA copies/10 μl of template). Very high DNA titres were observed in the bone marrow (median titre of 4.39 × 10^8^ in dogs infected with CPV-2a). The urinary tract was found to contain the lowest CPV-2 DNA amounts, with median titres of about 10^5^ DNA copies/10 μl of template in the bladder of all examined dogs. Surprisingly, viral DNA was detected also in the nervous tissues, including brain, cerebellum and cerebral bulb, with median titres above 10^6^ DNA copies/10 μl of template in all dogs. Faecal samples contained lower viral quantities than internal organs, with titres ranging between 3.71 × 10^7^ and 8.10 × 10^7^ DNA copies/10 μl of template for types 2c and 2a, respectively.Fig. 1Viral DNA loads detected by real-time PCR in tissues of dogs infected naturally by the antigenic variants of CPV-2. Viral titres are expressed as median log~10~ DNA copy numbers/10 μl of template. Ln, lymph node.

4. Discussion
=============

CPV infects dogs through the oronasal route and reaches the intestinal mucosa after an initial spread to lymphoid tissues ([@bib3]). Viraemia may reach very high titres of viral DNA and persist for several weeks, even after the virus has disappeared from the intestinal content (Decaro et al., unpublished data). In this study, all tissues analysed were shown to contain CPV DNA, probably as a consequence of viral spread in the organism through the blood. The number of dogs was limited, with only four dogs analysed per each of the three CPV variants. In fact, in order to limit the variability of viral titres due to different ages, breeds and clinical courses of the disease, only pups were chosen that were mixed-bred, had approximately the same age and had died after a similar duration of disease (4--5 days) as a consequence of single CPV infection. Moreover, it was difficult to recruit dogs dead due to infection with CPV-2b, since this variant is disappearing progressively from the Italian dog population ([@bib32], [@bib33], [@bib14], [@bib16], [@bib17]), and only one type 2b strain has been detected in Italy in 2006 (Decaro et al., unpublished data).

Tissue distribution of CPV was found to have similar patterns in dogs infected by types 2a, 2b and 2c, revealing that the variants have the same biological behaviour. Parvovirus replication in dogs and cats takes place mainly in highly mitotically active tissues, such as bone marrow, lymphoid organs and intestinal crypts ([@bib3]). Involvement of the nervous tissues has been described in cats ([@bib8], [@bib54], [@bib51]), whereas in dogs CPV antigen has been never detected in neurons, despite the presence of neurodegeneration ([@bib1], [@bib52]).

In contrast with previous studies, we have demonstrated the presence at high titres of CPV nucleic acid in all tissues examined including brain, cerebellum and bulb. Whether the presence of viral DNA is associated to effective replication and expression of viral proteins in neurons should be assessed by identification of CPV antigens using supplementary techniques, such as immunohistochemistry.

CPV DNA titres detected in the faeces were generally lower than those observed in lymphoid organs. It has been shown previously that shedding of CPV DNA in the faeces reaches maximal loads in the first days after infection (with a peak at 7--8 days post-infection), with a rapid decrease already at 10--11 days post-infection ([@bib12], [@bib22]). Moreover, in the late stage of infection the high antibody levels in the gut lumen may sequestrate most of the virions, so that traditional tests, such as haemagglutination and virus isolation, give frequently false negative results ([@bib16], [@bib21]). The results of the present work indicate that in laboratories where molecular methods are not employed routinely, traditional diagnostic methods for detection of CPV in dead dogs should be carried out on the internal organs rather than on the faeces or intestinal contents.
